| Disclosure of categories of material financial assets and liabilities |
| | | | | | | | | | | | | | December 31, | | | | | 2024 | | 2023 | | 2022 | | Notes | | | | (Euro, in thousands) | | | Financial assets held at fair value through other comprehensive income | | | | | | | | | | | | Equity instruments | | € | 52,941 | | € | — | | € | — | | 16 | | | | | | | | | | | | | Financial assets held at fair value through profit or loss | | | | | | | | | | | | Equity instruments | | | — | | | 13,575 | | | — | | 16 | Contingent consideration receivable | | | 47,207 | | | — | | | — | | 5 | Financial investments | | | 1,484,599 | | | 1,316,805 | | | 1,292,514 | | 21 | Financial assets at amortized cost | | | | | | | | | | | | Financial investments | | | 1,768,917 | | | 2,200,893 | | | 2,293,431 | | 21 | Escrow account | | | 41,163 | | | — | | | — | | 5 | Cash and cash equivalents | | | 64,239 | | | 166,803 | | | 508,117 | | 22 | Restricted cash (current and non-current) | | | 1,985 | | | 5,533 | | | 4,569 | | 17 | Other non-current assets | | | 1,266 | | | 318 | | | 1,209 | | 17 | Trade receivables | | | 32,471 | | | 17,494 | | | 28,194 | | 20 | Total financial assets | | € | 3,494,788 | | € | 3,721,421 | | € | 4,128,033 | | | | | | | | | | | | | | | Financial liabilities held at fair value through profit or loss | | | | | | | | | | | | Current financial instruments | | € | 5 | | € | — | | € | 19 | | 26 | Current contingent consideration related to milestones CellPoint | | | — | | | — | | | 8,485 | | 26 | Non-current contingent consideration related to milestones CellPoint | | | 20,576 | | | 20,972 | | | 13,582 | | 26 | Financial liabilities at amortized cost | | | | | | | | | | | | Trade liabilities | | | 64,230 | | | 87,966 | | | 68,928 | | 26 | Lease liabilities | | | 11,722 | | | 9,596 | | | 21,901 | | 25 | Current deferred consideration payable CellPoint | | | — | | | — | | | 6,222 | | 26 | Total financial liabilities | | € | 96,533 | | € | 118,534 | | € | 119,137 | | |
|